ILTOO Pharma is pleased to welcome the publication in The Lancet of the results from the MIROCALS phase IIb clinical trial shows that low-dose interleukin-2, a therapy pioneered by ILTOO Pharma, significantly improves survival and slows functional decline in patients with Amyotrophic Lateral Sclerosis, a fatal neurological disease with limited therapeutic options.